Cancer has been seriously threatening the health and life of humans for a longperiod.Despite the intensive effort put into revealing the underlying mechanismsof cancer,the detailled machinery of carcinogenesis is still far from fully understood.Numerous studies have illustrated that cell signaling is extensively involved intumor initiation,promotion and progression.Therefore,targeting the key mol-ecules in the oncogenic signaling pathway might be one of the most promisingways to conquer cancer.Some targeted drugs,such as imatinib mesylate (Gleevec),herceptin,gefitinib (Iressa),sorafenib (Nexavar) and sunitinib (Sutent),whichevolve from monotarget drug into multitarget ones,have been developed withencouraging effects. Cancer has been seriously threatening the health and life of humans for a long period. Despite these efforts into putting reveal the underlying mechanisms of cancer, the detailled machinery of carcinogenesis is still far from fully understood. Numerous studies have illustrated that cell signaling is extensively involved intumor initiation, promotion and progression.Therefore, targeting the key mol-ecules in the oncogenic signaling pathway might be one of the most promising vehicles to conquer cancer .ome targeted drugs, such as imatinib mesylate (Gleevec), herceptin, gefitinib (Iressa), sorafenib (Nexavar) and sunitinib (Sutent), whichevolve from monotarget drug into multitarget ones, have been developed withencouraging effects.